Skip to main content

Table 1 Clinicopathological features of breast cancer patients studied

From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

n=96 Prior to chemotherapy After chemotherapy
Tumour size 1,5-13 cm 0,3-14 cm
  cT1 1 (1%) ypT0 6 (6%)
  -a   ypT1 20 (21%)
  -b   -a 2
  -c 1 -b 11
  cT2 25 (26%) -c 7
  cT3 22 (23%) ypT2 31 (32%)
  cT4 41 (43%) ypT3 24 (25%)
  -b 19 ypT4 7 (7%)
  -d 22 -b 6
  NA 7 (7%) -d 1
    No surgery 8 (9%)
Lymph node status cN0 10 (11%) pN0 25 (26%)
  cN1 62 (64%) pN1 27 (28%)
  cN2   pN2 12 (12%)
  cN3 3 (3%) pN3 14 (15%)
    No surgery 8 (9%)
  NA 21 (22%) NA 10 (10%)
ER status Positive 68 (71%) Positive 59 (62%)
  Negative 25 (26%) Negative 16 (17%)
  NA 3 (3%) NA 21 (21%)
    ypT0, no surgery  
PR status Positive 59 (62%) Positive 46 (48%)
  Negative 34 (35%) Negative 29 (31%)
  NA 3 (3%) NA 21 (21%)
    ypT0, no surgery  
HER2 status Positive 28 (29%) Positive 18 (19%)
  Negative 65 (68%) Negative 57 (60%)
  NA 3 (3%) NA 21 (21%)
    ypT0, no surgery  
Ki67 status 0 2 (2%) 0 22 (28%)
  1 (0-1%) 12 (15%) 1 21 (27%)
  2 (1-5%) 19 (23%) 2 11 (14%)
  3 (5-10%) 13 (16%) 3 3 (4%)
  4 (10-15%) 6 (7%) 4 1 (1%)
  5 (15-20%) 4 (5%) 5 6 (8%)
  6 (20-33%) 2 (2%) 6 1 (1%)
  7 (33-50%) 4 (5%) 7 2 (3%)
  8 (50-66%) 1 (1%) 8 0 (0%)
  9 (66-80%) 3 (4%) 9 3 (4%)
  10 (80-100%) 1 (1%) 10 2 (3%)
  NA 14 (17%) NA 7 (9%)
  64+17 (100%) 64+15 (100%)
  1. NA: Accurate data are not available.